Biosimilars Working Group Responds to Phase II of the BC PharmaCare Biosimilars Initiative
September 23, 2019
Biosimilars Working Group Responds to Phase II of the BC PharmaCare Biosimilars Initiative VANCOUVER, BC – Wednesday, September 18, 2019. On September 5, 2019, the BC government announced phase two of its Biosimilars Initiative, informing patients prescribed the originator biologic drug, Remicade® (infliximab), to treat inflammatory bowel disease (Crohn’s disease and ulcerative colitis) that this medication […]